You can find more information about
cyclin-dependent-like kinase clk3
using the following links:
PlasmoDB - the Plasmodium genome resource
The TDR Targets Database
Subcellular Localization
Picture 1
Picture 2
Affecting Drugs
Drug Name
PubMed Articles (year of publication)
4-(2-{2-Methoxy-5-[(morpholin-4-yl)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-(propan-2-yl)benzoic Acid
Development of Potent Pf CLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials(2020)
Altiratinib
Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase(2022)
Aminopyrimidines
Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission(2014)
Oxo-b-carbolines
Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission(2014)
TCMDC-135051
Validation of the protein kinase Pf CLK3 as a multistage cross-species malarial drug target(2019)